Paris, France: 27 July 2023Ipsen , a global specialty-care biopharmaceutical company, presents today its financial results for the first half of 2023. H1 2023 total sales up by 7.4% at CER1 , with.
Ipsen Pharma: Ipsen delivers solid H1 2023 results and upgrades its full-year guidance finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
French drugmaker Ipsen said on Wednesday the European Commission has not granted marketing authorization for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva.